pharmaceutical-investing BetterLife To Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
pharmaceutical-investing BetterLife's Non-hallucinogenic LSD For Treating Mood Disorders Highlighted in Drug Discovery & Development Article
pharmaceutical-investing Promise of BetterLife's Non-hallucinogenic LSD For Treating Mood Disorders Highlighted in Medical Xpress Article
pharmaceutical-investing BetterLife Files Amended and Restated Offering Document for Offering of Units
pharmaceutical-investing Omineca Announces Upsized and Fully Allocated $2.8 Million Brokered Financing of Flow-Through Units
pharmaceutical-investing Betterlife Publishes Promising Results from a Study Titled "A Non-Hallucinogenic LSD Analog With Therapeutic Potential For Mood Disorders"
pharmaceutical-investing BetterLife Announces Engagement of Bloom Burton Securities Inc. and Provides Summary of 2022 Accomplishments
pharmaceutical-investing BetterLife To Present BETR-001 Preclinical Data at the 61ST Annual Meeting of the American College of Neuropsychopharmacology in Phoenix, Arizona
pharmaceutical-investing BetterLife Files Comprehensive Patent for BETR-001 and Other LSD Derivatives
